ICLR Icon | $136.07 -0.5% | 5/28/2026 | | Set Price Target | $145.00 | | 00.00% | View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 5/28/2026 |
BSX Boston Scientific | $48.32 -1.6% | 5/28/2026 | | Lower Price Target | $87.00 ➝ $74.00 | Outperform | 00.00% | View details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 5/28/2026 |
EQ Equillium | $2.90 +2.1% | 5/28/2026 | | Upgrade | $1.00 ➝ $6.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Equillium (NASDAQ:EQ) on 5/28/2026 |
LLY Eli Lilly and Company | $1,105.37 -1.9% | 5/26/2026 | | Set Price Target | $1,119.00 | | 00.00% | View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 5/26/2026 |
SPTX Seaport Therapeutics | $18.19 -3.2% | 5/26/2026 | | Initiated Coverage | $35.00 | Outperform | 00.00% | View details for Leerink Partners rating of Seaport Therapeutics (NASDAQ:SPTX) on 5/26/2026 |
TWST Twist Bioscience | $66.87 -3.1% | 5/22/2026 | | Set Price Target | $80.00 | | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 5/22/2026 |
EHC Encompass Health | $105.98 +0.6% | 5/22/2026 | | Set Price Target | $152.00 | | 00.00% | View details for Leerink Partners rating of Encompass Health (NYSE:EHC) on 5/22/2026 |
ROIV Roivant Sciences | $29.99 +0.4% | 5/21/2026 | | Set Price Target | $42.00 | | 00.00% | View details for Leerink Partners rating of Roivant Sciences (NASDAQ:ROIV) on 5/21/2026 |
CGEN Compugen | $2.63 -5.4% | 5/21/2026 | | Lower Price Target | $13.00 ➝ $5.00 | Outperform | 00.00% | View details for Leerink Partners rating of Compugen (NASDAQ:CGEN) on 5/21/2026 |
IRD Opus Genetics | $4.36 +3.7% | 5/21/2026 | | Initiated Coverage | $10.00 | Outperform | 00.00% | View details for Leerink Partners rating of Opus Genetics (NASDAQ:IRD) on 5/21/2026 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
|
REGN Regeneron Pharmaceuticals | $614.78 -1.1% | 5/18/2026 | | Reiterated Rating | $792.00 ➝ $641.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 5/18/2026 |
ONC BeOne Medicines | $287.92 -0.9% | 5/15/2026 | | Boost Price Target | $364.00 ➝ $367.00 | Outperform | 00.00% | View details for Leerink Partners rating of BeOne Medicines (NASDAQ:ONC) on 5/15/2026 |
ANAB AnaptysBio | $55.67 -2.4% | 5/15/2026 | | Set Price Target | $90.00 | | 00.00% | View details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 5/15/2026 |
IMNM Immunome | $21.83 -3.1% | 5/15/2026 | | Lower Price Target | $37.00 ➝ $33.00 | Outperform | 00.00% | View details for Leerink Partners rating of Immunome (NASDAQ:IMNM) on 5/15/2026 |
STRO Sutro Biopharma | $29.23 -1.3% | 5/15/2026 | | Set Price Target | $38.00 ➝ $43.00 | Outperform | 00.00% | View details for Leerink Partners rating of Sutro Biopharma (NASDAQ:STRO) on 5/15/2026 |
RNA Avidity Biosciences | $13.00 -2.7% | 5/15/2026 | | Initiated Coverage | | Outperform | 00.00% | View details for Leerink Partners rating of Avidity Biosciences (NASDAQ:RNA) on 5/15/2026 |
DOCS Doximity | $21.35 +1.3% | 5/14/2026 | | Lower Price Target | $31.00 ➝ $25.00 | Outperform | 00.00% | View details for Leerink Partners rating of Doximity (NYSE:DOCS) on 5/14/2026 |
AIRS AirSculpt Technologies | $5.38 -2.9% | 5/14/2026 | | Set Price Target | $4.50 | | 00.00% | View details for Leerink Partners rating of AirSculpt Technologies (NASDAQ:AIRS) on 5/14/2026 |
ANTX Anthem | $4.33 -2.9% | 5/14/2026 | | Upgrade | $9.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Anthem (NASDAQ:ANTX) on 5/14/2026 |
TNGX Tango Therapeutics | $21.98 +9.9% | 5/14/2026 | | Boost Price Target | $28.00 ➝ $55.00 | Outperform | 00.00% | View details for Leerink Partners rating of Tango Therapeutics (NASDAQ:TNGX) on 5/14/2026 |
JNJ Johnson & Johnson | $225.16 -2.4% | 5/13/2026 | | Upgrade | $265.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Johnson & Johnson (NYSE:JNJ) on 5/13/2026 |
AURA Aura Biosciences | $7.47 -0.4% | 5/12/2026 | | Set Price Target | $17.00 | | 00.00% | View details for Leerink Partners rating of Aura Biosciences (NASDAQ:AURA) on 5/12/2026 |
ALMR Alamar Biosciences | $20.44 +3.4% | 5/12/2026 | | Initiated Coverage | $35.00 | Outperform | 00.00% | View details for Leerink Partners rating of Alamar Biosciences (NASDAQ:ALMR) on 5/12/2026 |
KLRA Kailera Therapeutics | $22.99 +0.2% | 5/12/2026 | | Initiated Coverage | $36.00 | Outperform | 00.00% | View details for Leerink Partners rating of Kailera Therapeutics (NASDAQ:KLRA) on 5/12/2026 |
ENGN enGene | $1.85 +3.9% | 5/8/2026 | | Downgrade | $2.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of enGene (NASDAQ:ENGN) on 5/8/2026 |
GILD Gilead Sciences | $134.43 -1.3% | 5/8/2026 | | Lower Price Target | $148.00 ➝ $146.00 | | 00.00% | View details for Leerink Partners rating of Gilead Sciences (NASDAQ:GILD) on 5/8/2026 |
PODD Insulet | $144.94 +1.6% | 5/7/2026 | | Lower Price Target | $360.00 ➝ $247.00 | | 00.00% | View details for Leerink Partners rating of Insulet (NASDAQ:PODD) on 5/7/2026 |
TWST Twist Bioscience | $66.87 -3.1% | 5/5/2026 | | Upgrade | $70.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 5/5/2026 |
ICLR Icon | $136.07 -0.5% | 5/4/2026 | | Set Price Target | $125.00 | | 00.00% | View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 5/4/2026 |
ORKA Oruka Therapeutics | $58.53 +0.9% | 4/30/2026 | | Set Price Target | $120.00 | | 00.00% | View details for Leerink Partners rating of Oruka Therapeutics (NASDAQ:ORKA) on 4/30/2026 |
ALGN Align Technology | $174.95 +1.0% | 4/30/2026 | | Boost Price Target | $225.00 ➝ $230.00 | | 00.00% | View details for Leerink Partners rating of Align Technology (NASDAQ:ALGN) on 4/30/2026 |
HUM Humana | $305.97 -0.9% | 4/30/2026 | | Boost Price Target | $185.00 ➝ $255.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Humana (NYSE:HUM) on 4/30/2026 |
KALV KalVista Pharmaceuticals | $26.85 +0.3% | 4/29/2026 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Leerink Partners rating of KalVista Pharmaceuticals (NASDAQ:KALV) on 4/29/2026 |
NEO NeoGenomics | $10.52 +3.2% | 4/29/2026 | | Upgrade | $12.00 ➝ $25.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of NeoGenomics (NASDAQ:NEO) on 4/29/2026 |
ANAB AnaptysBio | $55.67 -2.4% | 4/28/2026 | | Boost Price Target | $66.00 ➝ $85.00 | Outperform | 00.00% | View details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 4/28/2026 |
CRMD CorMedix | $8.44 +0.2% | 4/28/2026 | | Boost Price Target | $13.00 ➝ $14.00 | Outperform | 00.00% | View details for Leerink Partners rating of CorMedix (NASDAQ:CRMD) on 4/28/2026 |
NTLA Intellia Therapeutics | $14.07 +2.9% | 4/27/2026 | | Set Price Target | $35.00 | | 00.00% | View details for Leerink Partners rating of Intellia Therapeutics (NASDAQ:NTLA) on 4/27/2026 |
HCA HCA Healthcare | $377.72 -1.7% | 4/27/2026 | | Lower Price Target | $573.00 ➝ $500.00 | Outperform | 00.00% | View details for Leerink Partners rating of HCA Healthcare (NYSE:HCA) on 4/27/2026 |
LLY Eli Lilly and Company | $1,105.37 -1.9% | 4/27/2026 | | Lower Price Target | $1,296.00 ➝ $1,058.00 | Outperform | 00.00% | View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 4/27/2026 |
TRAX First Tracks Biotherapeutics | $15.96 +0.9% | 4/24/2026 | | Initiated Coverage | $46.00 | Outperform | 00.00% | View details for Leerink Partners rating of First Tracks Biotherapeutics (NASDAQ:TRAX) on 4/24/2026 |
Before you buy SpaceX shares, consider this alternative approach (Ad) SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history.
But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered. Discover the overlooked SpaceX IPO strategy before the June listing |
ELV Elevance Health | $394.40 +0.4% | 4/23/2026 | | Set Price Target | $364.00 | | 00.00% | View details for Leerink Partners rating of Elevance Health (NYSE:ELV) on 4/23/2026 |
BBNX Beta Bionics | $12.12 +0.2% | 4/22/2026 | | Lower Price Target | $25.00 ➝ $24.00 | Outperform | 00.00% | View details for Leerink Partners rating of Beta Bionics (NASDAQ:BBNX) on 4/22/2026 |
DFTX Definium Therapeutics | $24.19 +3.0% | 4/22/2026 | | Boost Price Target | $23.00 ➝ $30.00 | Outperform | 00.00% | View details for Leerink Partners rating of Definium Therapeutics (NASDAQ:DFTX) on 4/22/2026 |
DNLI Denali Therapeutics | $21.04 +0.4% | 4/22/2026 | | Lower Price Target | $40.00 ➝ $35.00 | Outperform | 00.00% | View details for Leerink Partners rating of Denali Therapeutics (NASDAQ:DNLI) on 4/22/2026 |
ISRG Intuitive Surgical | $424.59 +0.2% | 4/22/2026 | | Lower Price Target | $622.00 ➝ $573.00 | Outperform | 00.00% | View details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 4/22/2026 |
JAZZ Jazz Pharmaceuticals | $236.49 +0.5% | 4/22/2026 | | Boost Price Target | $215.00 ➝ $225.00 | Outperform | 00.00% | View details for Leerink Partners rating of Jazz Pharmaceuticals (NASDAQ:JAZZ) on 4/22/2026 |
MANE MANE | $101.01 -1.8% | 4/22/2026 | | Boost Price Target | $75.00 ➝ $90.00 | Outperform | 00.00% | View details for Leerink Partners rating of MANE (NYSE:MANE) on 4/22/2026 |
NBIX Neurocrine Biosciences | $158.30 +1.2% | 4/22/2026 | | Boost Price Target | $160.00 ➝ $170.00 | Outperform | 00.00% | View details for Leerink Partners rating of Neurocrine Biosciences (NASDAQ:NBIX) on 4/22/2026 |
UNH UnitedHealth Group | $379.70 -0.7% | 4/22/2026 | | Boost Price Target | $345.00 ➝ $400.00 | Outperform | 00.00% | View details for Leerink Partners rating of UnitedHealth Group (NYSE:UNH) on 4/22/2026 |
ABT Abbott Laboratories | $85.36 -1.1% | 4/21/2026 | | Lower Price Target | $119.00 ➝ $106.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Abbott Laboratories (NYSE:ABT) on 4/21/2026 |
RCUS Arcus Biosciences | $25.32 +3.4% | 4/20/2026 | | Set Price Target | $47.00 | | 00.00% | View details for Leerink Partners rating of Arcus Biosciences (NYSE:RCUS) on 4/20/2026 |
SNSE Sensei Biotherapeutics | $21.14 +20.2% | 4/20/2026 | | Initiated Coverage | $50.00 | Outperform | 00.00% | View details for Leerink Partners rating of Sensei Biotherapeutics (NASDAQ:SNSE) on 4/20/2026 |
JNJ Johnson & Johnson | $225.16 -2.4% | 4/15/2026 | | Boost Price Target | $232.00 ➝ $252.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Johnson & Johnson (NYSE:JNJ) on 4/15/2026 |
REPL Replimune Group | $8.69 +85.7% | 4/13/2026 | | Reiterated Rating | $11.00 ➝ $2.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Replimune Group (NASDAQ:REPL) on 4/13/2026 |
SYK Stryker | $305.73 -0.6% | 4/13/2026 | | Initiated Coverage | $410.00 | Outperform | 00.00% | View details for Leerink Partners rating of Stryker (NYSE:SYK) on 4/13/2026 |
SYRE Spyre Therapeutics | $73.50 +1.9% | 4/13/2026 | | Boost Price Target | $49.00 ➝ $106.00 | Outperform | 00.00% | View details for Leerink Partners rating of Spyre Therapeutics (NASDAQ:SYRE) on 4/13/2026 |
ZBH Zimmer Biomet | $82.46 -0.4% | 4/13/2026 | | Initiated Coverage | $101.00 | Hold | 00.00% | View details for Leerink Partners rating of Zimmer Biomet (NYSE:ZBH) on 4/13/2026 |
STRO Sutro Biopharma | $29.23 -1.3% | 4/7/2026 | | Initiated Coverage | $38.00 | Outperform | 00.00% | View details for Leerink Partners rating of Sutro Biopharma (NASDAQ:STRO) on 4/7/2026 |
MSLE Satellos Bioscience | $7.30 +3.8% | 4/6/2026 | | Initiated Coverage | $20.00 | Outperform | 00.00% | View details for Leerink Partners rating of Satellos Bioscience (NASDAQ:MSLE) on 4/6/2026 |
CAMP CAMP4 Therapeutics | $4.39 -2.2% | 4/2/2026 | | Boost Price Target | $8.00 ➝ $9.00 | Outperform | 00.00% | View details for Leerink Partners rating of CAMP4 Therapeutics (NASDAQ:CAMP) on 4/2/2026 |
CNTA Centessa Pharmaceuticals | $39.76 -0.1% | 4/1/2026 | | Downgrade | $36.00 ➝ $40.00 | Outperform ➝ Hold | 00.00% | View details for Leerink Partners rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 4/1/2026 |
INSM Insmed | $106.91 -1.3% | 3/24/2026 | | Boost Price Target | $210.00 ➝ $215.00 | Outperform | 00.00% | View details for Leerink Partners rating of Insmed (NASDAQ:INSM) on 3/24/2026 |
ANL Adlai Nortye | $11.94 +5.7% | 3/20/2026 | | Initiated Coverage | $23.00 | Outperform | 00.00% | View details for Leerink Partners rating of Adlai Nortye (NASDAQ:ANL) on 3/20/2026 |
PTGX Protagonist Therapeutics | $99.56 -0.8% | 3/19/2026 | | Boost Price Target | $107.00 ➝ $110.00 | Outperform | 00.00% | View details for Leerink Partners rating of Protagonist Therapeutics (NASDAQ:PTGX) on 3/19/2026 |
BTSG BrightSpring Health Services | $61.68 +1.4% | 3/18/2026 | | Reiterated Rating | $49.00 | Outperform | 00.00% | View details for Leerink Partners rating of BrightSpring Health Services (NASDAQ:BTSG) on 3/18/2026 |
COR Cencora | $269.21 +0.6% | 3/17/2026 | | Reiterated Rating | | Outperform | 00.00% | View details for Leerink Partners rating of Cencora (NYSE:COR) on 3/17/2026 |
GPCR Structure Therapeutics | $39.34 -2.1% | 3/16/2026 | | Reiterated Rating | | Outperform | 00.00% | View details for Leerink Partners rating of Structure Therapeutics (NASDAQ:GPCR) on 3/16/2026 |
HIMS Hims & Hers Health | $26.12 +2.9% | 3/16/2026 | | Boost Price Target | $17.50 ➝ $25.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Hims & Hers Health (NYSE:HIMS) on 3/16/2026 |
ORKA Oruka Therapeutics | $58.53 +0.9% | 3/16/2026 | | Boost Price Target | $58.00 ➝ $86.00 | Outperform | 00.00% | View details for Leerink Partners rating of Oruka Therapeutics (NASDAQ:ORKA) on 3/16/2026 |
IPSC Century Therapeutics | $2.45 +2.9% | 3/13/2026 | | Set Price Target | $2.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Century Therapeutics (NASDAQ:IPSC) on 3/13/2026 |
ARDX Ardelyx | $6.04 -3.4% | 3/12/2026 | | Reiterated Rating | | Outperform | 00.00% | View details for Leerink Partners rating of Ardelyx (NASDAQ:ARDX) on 3/12/2026 |
TNYA Tenaya Therapeutics | $0.87 +8.8% | 3/12/2026 | | Reiterated Rating | $2.00 | Outperform | 00.00% | View details for Leerink Partners rating of Tenaya Therapeutics (NASDAQ:TNYA) on 3/12/2026 |
RIVN Rivian Automotive | $16.30 +7.2% | 3/12/2026 | | Reiterated Rating | | Outperform | 00.00% | View details for Leerink Partners rating of Rivian Automotive (NASDAQ:RIVN) on 3/12/2026 |
BBIO BridgeBio Pharma | $66.26 -3.2% | 3/12/2026 | | Reiterated Rating | $98.00 | Outperform | 00.00% | View details for Leerink Partners rating of BridgeBio Pharma (NASDAQ:BBIO) on 3/12/2026 |
VCEL Vericel | $33.33 -2.7% | 3/10/2026 | | Reiterated Rating | $46.00 | Outperform | 00.00% | View details for Leerink Partners rating of Vericel (NASDAQ:VCEL) on 3/10/2026 |
ZTS Zoetis | $77.81 -0.6% | 3/10/2026 | | Reiterated Rating | | Market Perform | 00.00% | View details for Leerink Partners rating of Zoetis (NYSE:ZTS) on 3/10/2026 |
MDT Medtronic | $73.73 -2.4% | 3/10/2026 | | Reiterated Rating | $119.00 | Outperform | 00.00% | View details for Leerink Partners rating of Medtronic (NYSE:MDT) on 3/10/2026 |
CYTK Cytokinetics | $76.76 -0.1% | 3/10/2026 | | Reiterated Rating | | Outperform | 00.00% | View details for Leerink Partners rating of Cytokinetics (NASDAQ:CYTK) on 3/10/2026 |
DDD 3D Systems | $3.55 +1.4% | 3/10/2026 | | Reiterated Rating | | Outperform | 00.00% | View details for Leerink Partners rating of 3D Systems (NYSE:DDD) on 3/10/2026 |
SPRY ARS Pharmaceuticals | $9.07 -3.5% | 3/10/2026 | | Set Price Target | $26.00 | Outperform | 00.00% | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 3/10/2026 |
CAH Cardinal Health | $196.57 -1.6% | 3/9/2026 | | Reiterated Rating | $275.00 | Outperform | 00.00% | View details for Leerink Partners rating of Cardinal Health (NYSE:CAH) on 3/9/2026 |
HSIC Henry Schein | $76.58 +0.3% | 3/9/2026 | | Reiterated Rating | | Market Perform | 00.00% | View details for Leerink Partners rating of Henry Schein (NASDAQ:HSIC) on 3/9/2026 |
CRMD CorMedix | $8.44 +0.2% | 3/6/2026 | | Reiterated Rating | $13.00 | Outperform | 00.00% | View details for Leerink Partners rating of CorMedix (NASDAQ:CRMD) on 3/6/2026 |
ARDT Ardent Health | $9.21 -2.7% | 3/6/2026 | | Lower Price Target | $16.00 ➝ $15.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ardent Health (NYSE:ARDT) on 3/6/2026 |
AMGN Amgen | $336.79 +0.1% | 3/5/2026 | | Reiterated Rating | $355.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Amgen (NASDAQ:AMGN) on 3/5/2026 |
CVS CVS Health | $90.97 -2.2% | 3/5/2026 | | Reiterated Rating | $98.00 | Outperform | 00.00% | View details for Leerink Partners rating of CVS Health (NYSE:CVS) on 3/5/2026 |
MCK McKesson | $741.47 -2.0% | 3/5/2026 | | Reiterated Rating | $1,085.00 | Outperform | 00.00% | View details for Leerink Partners rating of McKesson (NYSE:MCK) on 3/5/2026 |
CLOV Clover Health Investments | $3.98 -4.8% | 3/5/2026 | | Lower Price Target | $3.00 ➝ $2.50 | Market Perform | 00.00% | View details for Leerink Partners rating of Clover Health Investments (NASDAQ:CLOV) on 3/5/2026 |
BHVN Biohaven | $11.02 +7.6% | 3/3/2026 | | Reiterated Rating | $15.00 | Outperform | 00.00% | View details for Leerink Partners rating of Biohaven (NYSE:BHVN) on 3/3/2026 |
SGP Spyglass Pharma | $19.26 -2.9% | 3/3/2026 | | Downgrade | | Market Perform | 00.00% | View details for Leerink Partners rating of Spyglass Pharma (NASDAQ:SGP) on 3/3/2026 |
Before you buy SpaceX shares, consider this alternative approach (Ad) SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history.
But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered. Discover the overlooked SpaceX IPO strategy before the June listing |
AGMB AgomAb Therapeutics | $11.25 -2.5% | 3/3/2026 | | Initiated Coverage | $36.00 | Outperform | 00.00% | View details for Leerink Partners rating of AgomAb Therapeutics (NASDAQ:AGMB) on 3/3/2026 |
IONS Ionis Pharmaceuticals | $76.50 -1.1% | 3/3/2026 | | Boost Price Target | $102.00 ➝ $104.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 3/3/2026 |
NTLA Intellia Therapeutics | $14.07 +2.9% | 3/3/2026 | | Boost Price Target | $27.00 ➝ $29.00 | Outperform | 00.00% | View details for Leerink Partners rating of Intellia Therapeutics (NASDAQ:NTLA) on 3/3/2026 |
SGP Spyglass Pharma | $19.26 -2.9% | 3/3/2026 | | Initiated Coverage | $42.00 | Outperform | 00.00% | View details for Leerink Partners rating of Spyglass Pharma (NASDAQ:SGP) on 3/3/2026 |
ZYME Zymeworks | $25.13 -1.4% | 3/3/2026 | | Boost Price Target | $52.00 ➝ $58.00 | Outperform | 00.00% | View details for Leerink Partners rating of Zymeworks (NASDAQ:ZYME) on 3/3/2026 |
QURE uniQure | $28.53 +14.8% | 3/2/2026 | | Reiterated Rating | $35.00 | Outperform | 00.00% | View details for Leerink Partners rating of uniQure (NASDAQ:QURE) on 3/2/2026 |
CAH Cardinal Health | $196.57 -1.6% | 3/2/2026 | | Boost Price Target | $268.00 ➝ $275.00 | Outperform | 00.00% | View details for Leerink Partners rating of Cardinal Health (NYSE:CAH) on 3/2/2026 |
MANE MANE | $101.01 -1.8% | 3/2/2026 | | Initiated Coverage | $75.00 | Outperform | 00.00% | View details for Leerink Partners rating of MANE (NYSE:MANE) on 3/2/2026 |
RCUS Arcus Biosciences | $25.32 +3.4% | 3/2/2026 | | Boost Price Target | $36.00 ➝ $49.00 | Outperform | 00.00% | View details for Leerink Partners rating of Arcus Biosciences (NYSE:RCUS) on 3/2/2026 |
CERT Certara | $5.82 +2.6% | 2/26/2026 | | Reiterated Rating | $10.00 | Outperform | 00.00% | View details for Leerink Partners rating of Certara (NASDAQ:CERT) on 2/26/2026 |